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Abstract 
The aim of this study is the development of nanoemulsions for intravenous administration of Sorafenib, which is a 
poorly soluble drug with no parenteral treatment. The formulation was prepared by a high energy emulsification 
method and optimized by response surface methodology. The effects of overhead stirring time, high shear rate, high 
shear time, and cycles of high-pressure homogenizer were studied in the preparation of nanoemulsion loaded with 
Sorafenib. Most of the particles in nanoemulsion are spherical in shape, the smallest particle size being 82.14 nm. 
The results of the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole reveal that the optimum 
formulation does not affect normal cells significantly in low drug concentrations but could remove the cancer cells. 
Finally, a formulation containing Sorafenib retained its properties over a period of 90 days. With characterization, the 
study of the formulated nanoemulsion has the potential to be used as a parenteral nanoemulsion in the treatment of 
cancer. 
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Background
Cancer is well known as a fatal disease. It has been found 
that the rate of survival of cancer-stricken patients has 
not increased prominently over the last 30  years [1]. 
Among the key challenges in the successful treatment 
of cancer patients is the issue of drug resistance over a 
long period of time. The advantage of nanotechnology 
has increased the number of research in this area and 
carriers of nanoemulsion have been found to be an effec-
tive method of resolving the issue of drug resistance to 
chemotherapy drugs for cancer [2]. There are many ben-
efits attached to the drug delivery systems, which include 
the increase of drug stability in vivo, improved effects of 
retention and permeability, as well as the ease of surface 
modification [3, 4]. Nanotechnology has been utilized in 
various ways over the past decade, including food tech-
nology, pesticide use in agriculture, cosmetics, as well as 
pharmaceuticals [5, 6]. Most pharmacy-related nanocar-
riers, such as nanoparticles, nanoemulsions, and nano-
capsules have been developed to control active biological 
drugs. These drugs have been encapsulated with nano-
carriers for treatments to deal with controlled release 
and different parenteral, intranasal, oral, as well as trans-
dermal routes [7]. Nanoemulsions are heterogeneous 
in the 20–200  nm range, whereas immiscible solutions 
consisting of oil and aqueous ingredients can lead to the 
dispersal stage [8, 9]. The above-mentioned system has 
the capability to dissolve large amounts of drugs with the 
lipophilic features. Moreover, it has the ability to reduce 
the degradation of drugs by enzymes [10]. Nanoemulsion 
was utilized in this research as a Sorafenib nanocarrier, 
with the anticipated capability of reducing the clearance 
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rate in future biological studies. Nanoemulsion similarly 
needs high-energy input, which is dissipated across mas-
sive areas during the process of emulsification [11].
According to preclinical trials for several medical types 
of research, Sorafenib (Fig.  1) is a molecule that inhib-
its tumor-cell proliferation, [12] with its ability to bind 
plasma proteins (99.5%), mainly due to albumin. In addi-
tion, it can also be metabolized in the liver. Nevertheless, 
Sorafenib is poorly soluble in water [13, 14] with a low 
bioavailability (38–49%) value.
Some main drawbacks of the specific drugs for anti-
cancer use include poor solubility, intense cytotoxicity 
in healthy tissue [15], as well as an inability to accurately 
select tumor tissues; this results in harsh side effects, 
leading to poor cure rates. Therefore, it is difficult to use 
the conventional drug delivery approach for targeted 
abnormal cells [16]. Most drugs are still being investi-
gated for the development of a maximized therapeutic 
value as well as a minimized or negligible amount of side 
effects, which includes gastrointestinal (nausea, diarrhea, 
constipation, vomiting), dermatological, constitutional 
(loss of weight, exhaustion), cardiovascular (hyperten-
sion), as well as painful pulmonary occurrences. Research 
shows that the nanoparticle carriers for chemotherapy 
drugs are effective methods of overcoming the resistance 
to cancer drugs [2]. Among the most widely used and 
effective path to the administration of drugs is the par-
enteral drug delivery system that is normally utilized for 
low bioavailability actives as well as for slim therapeutic 
indexes [10, 17]. Even though many nanoemulsion sys-
tems have been documented, only a few of these can be 
utilized for the parenteral delivery system due to the sur-
factant’s toxicity [8].
A common multivariate statistical technique used to 
determine optimal conditions is response surface meth-
odology (RSM) [18]. This is the statistical, mathemati-
cal, and technical model that is capable of assessing the 
interactions and relationship between independent vari-
ables (factors) and dependent variables (response) [19]. 
RSM was employed to study the optimal conditions 
at the low composition of surfactant in nanoemulsion 
containing Sorafenib. The central composite rotatable 
design (CCRD) was applied to study the effects of four 
independent variables, time of stirring overhead, rate and 
time of high shear, and the cycle of the homogenizer of 
high pressure, on the one dependant variable (result), 
namely particle size. RSM allows nanoemulsion devel-
opment to be completed in a decreasing number of tests 
with a desirable result in the optimal condition. The 
objective of this study was the optimization of nanoemul-
sion condition containing Sorafenib as a parenteral drug 
delivery system using RSM for the treatment of tumor-
cell proliferation.
Results and discussion
Solubility of Sorafenib in selected oils
The Sorafenib’s solubility in different forms of oil within 
the Lecithin solution is shown in Fig.  2. The findings 
reveal that the drug only dissolves in MCT and drug pre-
cipitation was not seen at the bottom of the test tube. 
On the contrary, precipitation was observed in other oil 
bases such as olive, castor, and soybean oils. It is pos-
sible to dissolve Sorafenib in MCT as it has a compara-
tively shorter fatty acid chain in the MCT. This oil is the 
desired potential carrier to deliver active components 
into the human body. Adding lecithin in this formula-
tion increases the Sorafenib’s solubility. The drug load-
ing for each formulation in the emulsion systems design 
for weak water soluble drugs is an essential design com-
ponent that depends on the solubility of the drug in dif-
ferent components of the formulation. The formulation 
volume must be reduced to administer the therapeutic 
drug dose in a capsule form. The selected oil for the for-
mulation must be able to dissolve the drug at a high level 
to achieve a concentrated nanoemulsion form.
Screening the independent variables
A study was carried out to evaluate the levels of inde-
pendent variables (not mentioned). Based on these 
results, the lower, central and higher levels of four inde-
pendent variables, the range of overhead stirring time of 
80–240 min, high shear stirring time of 10–30 min, high 
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Fig. 1 Molecular structure of Sorafenib
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shear rate of 800–5600 rpm, and the cycle of high-pres-
sure homogenizer of 8 cycles to 20 cycles, were selected. 
Within this range, nanoemulsion formulation contain-
ing Sorafenib produced the particle size below 121  nm, 
a polydispersity index of 0.270, and the zeta potential of 
more or less ± 25 mV.
Statistical analysis and model fitting
The experimental design for the independent variables and 
their responses (size of the particle) based on the design 
of the CCRD matrix is depicted in Table  1. This study 
employs four variables, a five level CCRD that includes 6 
replications at the center point using 30 runs. The formu-
lation of the nanoemulsion with the Sorafenib revealed a 
size of a particle within the 75.28–107.36 nm range.
The independent variables’ p and F values while pre-
paring the nanoemulsions and their estimation of the 
coefficient of the nanoemulsion formulation’s particle 
size, which contains the Sorafenib, is depicted in Table 2. 
A value that is positive predicts the efficacy of advocat-
ing optimization because of the effect of synergy, while a 
value that is negative is expressed as the opposite effect of 
an inverse link between a factor and its response. The P 
value is a factor that is utilized to monitor every variable’s 
meaning and it reveals the interaction’s intensity between 
every independent variable [20]. The analyzed data 
utilizing ANOVA reveals a P value of lower than 0.05 
(P = 0.1859) and a higher quantity of F-value is regarded 
as being significant based on statistics [21]. The lack-of-
fit term is not significant as it is more than 0.05 and the 
cycle of homogenization’s (X4) linear term has the most 
significant (P < 0.0001) impact on the size of the particle 
with an F-value of 27.91.
Table  2 presents the analysis of the ANOVA and 
R-squared (R2) at size of particle. Moreover, the ANOVA 
analysis recommends the third-order polynomial 
response surface model with coefficient determination 
(R2) of 0.9022 for particle size. The ANOVA analysis of 
variance was used to examine the coefficient’s signifi-
cance and the modification versions of the quadratic pol-
ynomial. The model’s equation of the last third order 
polynomial (according to the values that are coded) for 
particle size is depicted in Eq. 1:
Response surface analysis
Figure  3 presents the particle’s minimum size retrieved 
in the 160–200 min, 3200–4400 rpm, 10–20 min range, 
and 14–17 cycles for their stirring overhead time, rate 
and time of high shear, and the cycle of the homogenizer 
of high pressure, respectively. The high-pressure homog-
enizer’s most successful variable is the cycle of a homog-
enizer of high pressure. As observed, increasing the 
high-pressure cycle and the time for an overhead stirring 
could increase the size of the particle.
The findings of this research revealed that the tiniest 
size of the particle could be retrieved during the over-
head stirring duration of 4000  rpm and 10  min of rate 
and high shearing time for high shearing, respectively. A 
particular additional increase in the size of the particle 
was noted as being carried out by some people. Rate and 
time with higher destabilization mechanisms, including 
(1)
Particle size (Y1) = +84.92−1.84 x1 + 0.32 x2
+ 0.044 x3 − 3.67 x4−1.33 x1x2
+ 1.04 x1x3−0.43 x1x4 + 2.23 x2x3
+ 1.87x2x4 + 0.75 x3x4 − 0.98 x
2
1
+ 0.43 x
2
2 + 0.75 x
2
3
+ 2.45 x
2
4−2.35 x1x2x3−5.78 x
2
1x2
Fig. 2 Solubility of Sorafenib in different types of oil containing 3% of lecithin
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coalescence and sedimentation, result in a final larger size 
or particle. The formation of the bigger particles across a 
longer duration could be related to the over processing 
of the emulsification, which could lead to coalescence. As 
earlier mentioned, some findings recorded for the nanoe-
mulsions emulsification used an ultrasonic approach. 
Some of the findings were recorded for nanoemulsions 
emulsification by utilizing the ultrasonic approach as 
mentioned above [22, 23].
Optimization of the preparation of nanoemulsion 
formulation containing Sorafenib
Table  3 shows the optimal nanoemulsion contain-
ing Sorafenib (50  mg). The conditions were an over-
head stirring time of 120  min, shear rate of 4000  rpm, 
shear time of 10 min, and the 16 cycles of high-pressure 
homogenizer, which produced a particle size of 82.14 nm. 
The optimization of the process was carried out to deter-
mine the formulation with the smallest particle size at 
low levels of the independent variables.
Transmission electron microscopy (TEM) analysis
Figure  4 shows the drug loaded nanoemulsion in the 
interlayer space and particle size distribution histo-
gram. The size distribution histograms of nanoemulsion 
were in agreement with the particle size. Results from 
TEM revealed that emulsion droplets were in an almost 
spherical shape. A similar result was obtained for paren-
teral nanoemulsions containing thalidomide [24]. It can 
be seen that the nanoemulsion with spherical morphol-
ogy disperses well without aggregation. An examination 
using a TEM analysis has been one of most performed 
Table 1 The matrix of actual and predicted values of particle size from CCRD experimental design
Run no. Overhead stirring time 
(min)
Shear rate (rpm) Shear time (min) Cycle of homogenizer 
(cycle)
Particle size (nm)
Actual Predicted
1 160.00 3200.00 10.00 14.00 102.20 104.96
2 200.00 2000.00 25.00 11.00 105.20 102.73
3 200.00 4400.00 25.00 11.00 81.83 83.81
4 160.00 3200.00 20.00 14.00 77.96 76.26
5 160.00 3200.00 20.00 8.00 93.45 92.32
6 120.00 4400.00 25.00 17.00 92.67 94.23
7 160.00 3200.00 20.00 14.00 89.24 89.48
8 240.00 3200.00 20.00 14.00 85.87 86.07
9 200.00 4400.00 15.00 17.00 90.20 88.55
10 200.00 4400.00 15.00 11.00 81.20 84.60
11 200.00 2000.00 25.00 17.00 82.18 84.26
12 120.00 2000.00 15.00 17.00 75.31 74.99
13 200.00 4400.00 25.00 17.00 82.99 88.31
14 80.00 3200.00 20.00 14.00 91.94 88.50
15 160.00 3200.00 30.00 14.00 82.53 83.54
16 160.00 5600.00 20.00 14.00 77.55 78.42
17 160.00 3200.00 20.00 14.00 88.90 84.68
18 120.00 4400.00 15.00 17.00 75.28 77.32
19 120.00 2000.00 15.00 11.00 87.10 86.01
20 200.00 2000.00 15.00 11.00 88.36 87.27
21 120.00 4400.00 25.00 11.00 88.77 87.82
22 160.00 3200.00 20.00 14.00 89.23 88.00
23 200.00 2000.00 15.00 17.00 101.67 102.04
24 160.00 3200.00 20.00 20.00 89.91 87.36
25 120.00 4400.00 15.00 11.00 81.84 84.92
26 160.00 800.00 20.00 14.00 84.53 84.92
27 160.00 3200.00 20.00 14.00 85.90 84.92
28 120.00 2000.00 25.00 17.00 87.52 84.92
29 120.00 2000.00 25.00 11.00 82.15 84.92
30 160.00 3200.00 20.00 14.00 87.56 84.92
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analyses for identifying the morphology and structure 
of components in the material structure and particle 
size frequency (or the average size of particles size dis-
tribution). The image of drug loaded nanoemulsion was 
clearly showed that the drug was encapsulated inside the 
oil particle in the nanoemulsion systems.
Stability of nanoemulsion formulation containing 
Sorafenib
Particle size plays an important role in assessing the sta-
bility of nanoemulsion. The effect of three different tem-
peratures (4 ± 2, 25 ± 2 and 45 ± 2 °C) was tested on the 
nanoemulsion formulation. Figure 5 represents the effect 
of time on the particle size. The formulation was stable 
for three months of storage at 4 °C without any significant 
changes in particle size but it was not stable at 25 and 
45 °C. The instability of the formulation could be due to 
the relatively high water content which leads to lower vis-
cosity [25]. Furthermore, the collision frequency between 
particles increases when the temperature is increased 
and this will lead to decreased colloidal stability. The for-
mulation was found to be stable for three months without 
any significant changes in particle size. The small sizes 
of the particles in the nanoemulsion formulation were 
able to overcome the gravitational force. In this case, the 
Brownian motion of the particle caused the emulsion to 
be stable against creaming and sedimentation. The floc-
culation of the particles was also prevented due to the 
small particle size, so no phase separation occurs and 
the system remains dispersed. The coalescence phenom-
enon, as another instability in the emulsions system, was 
prevented by the presence of small droplets. Since these 
droplets were not able to deform, fluctuations of the sur-
face were prevented [26].
MTT assay
Fibroblast cell line (3T3), as well as the liver cancer cell 
line (Hep G2), were utilized to evaluate the cultured 
cells’ nanoemulsion’s cytotoxicity. The nanoemulsion’s 
cytotoxicity depends on the focus and incubation that 
is based on the time of the MTT colorimetric assay to 
examine the 3T3 and the Hep G2 cells cellular response 
(Fig. 6). Five differing volume system ratios of the culture 
cells’ extracellular medium were applied for 24 and 48 h 
of incubation in this study. The findings of the MTT assay 
revealed that the relative viability reduces the growing 
number of samples while increasing the concentration 
of the sample to 70.75% at the highest concentration of 
1000 μg/ml for the 3T3 and relative viability reduces with 
the growing number of samples concentrated to 58.57% 
at the highest concentration of 50 μg/ml for the Hep G2 
cells. The cytotoxic effects of the nanoemulsion contain-
ing Sorafenib are on the 3T3 and Hep G2 cells where the 
highest concentration was determined and so the effec-
tive concentrations that caused 50% of the inhibitions of 
cell viability (IC50) for each compound could be deter-
mined. IC50 was achieved at a high drug concentration 
for normal cells and a low drug concentration for a can-
cer cells. 50% of cancer cells that remain alive revealed 
the high capability of the drug that is prepared in com-
parison with the findings that have been documented 
(85% remain alive) [27]. The results of the MTT revealed 
that the formulation that is optimum does not affect nor-
mal cells significantly in low drug concentrations but 
could remove the cancer cells. The MTT’s assay results 
were used to measure the toxicity.
Conclusion
Homogenizers of high shear and pressure were utilized in 
the nanoemulsion formulation because they performed 
better than homogenizers that had either high shear 
or high pressure. The response surface approach was 
used to optimize particle size. The variables consisted 
Table 2 Analysis of variance of the fitted modify quadratic 
equation for particle size and regression coefficients of the 
final reduced models
Source Coefficient estimate Mean square F-value P value
Model 84.92 86.66 7.49 0.0004
X1 −1.84 81.28 7.03 0.0200
X2 0.32 0.80 0.069 0.7969
X3 0.044 0.047 0.004099 0.9499
X4 −3.67 322.86 27.91 0.0001
X1 X2 −1.33 28.28 2.45 0.1419
X1 X3 1.04 17.15 1.48 0.2449
X1 X4 −0.43 2.95 0.26 0.6218
X2 X3 2.23 79.48 6.87 0.0211
X2 X4 1.87 55.73 4.82 0.0469
X3 X4 0.75 9.09 0.79 0.3914
X1
2 −0.98 26.28 2.27 0.1557
X2
2 0.43 5.09 0.44 0.5186
X3
2 0.75 15.36 1.33 0.2699
X4
2 2.45 164.08 14.19 0.0024
X2 X3 X4 −2.35 88.14 7.62 0.0162
X1
2X2 −5.78 178.00 15.39 0.0017
Residual 11.57 – –
Lack of fit 14.79 2.31 0.1859
Pure error 6.41 – –
R2 0.9022
Adjusted R2 0.7818
Predicted R2 0.1345
PRESS 1330.20
Adequate precision 11.708
Standard deviation 3.40
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Fig. 3 Response surface plots; the interaction effect of a overhead stirring time and the cycle of high pressure homogenizer; b high shear time and 
the cycle of high pressure homogenizer; c shear rate and the cycle of high pressure homogenizer on response (particle size)
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of the overhead stirring time, shear rate, shear time, 
and the cycle of high-pressure homogenizers. The high-
pressure homogenizer’s cycle had the most significant 
(P < 0.0001) effect on the particle size. Based on the TEM 
image, the particles are spherical with the average opti-
mum formulation of 82.14  nm, which is a crucial fac-
tor in the stability and penetration of the nanoemulsion 
system. The MTT result showed that the optimum for-
mulation did not significantly affect a normal cell at low 
drug concentrations, but could eliminate cancer cells. 
The nanoemulsion showed potential as a safe and effec-
tive parenteral delivery system for anticancer drugs. The 
optimum formulation can deliver Sorafenib into the body 
with less drug and higher efficacy than when Sorafenib 
is delivered in tablet form. The formulation exhibited 
very good stability in 3 months of storage. Therefore, the 
Sorafenib nanoemulsion could be used as a parenteral 
formulation and provide parenteral nutrition.
Methods
Materials
MCT (Pharmaceutical Grade), Glycerol and Lecithin 
(Lipoid S75) were purchased from Numedica, JT Baker 
(USA) and GmbH (Germany) respectively. Polysorbate 
80 (Tween80) was obtained from Fluka (Germany).The 
Sorafenib free base was obtained from Xi’an Yiyang Bio-
Tech Co., Ltd (China).
Selection of oils
The solubility of Sorafenib with four oil bases such as 
olive, castor, and soybean oils was investigated to find 
best solubilizing capacity in present and absent of leci-
thin. First, Sorafenib was added into the oil phase, then 
Table 3 The actual and predicted response values for the optimized nanoemulsion
Model Independent variable Particle size (nm)
Overhead stirring High shear rate High shear stirring time High pressure homogenizers Actual Predicted
Units (min) (rpm) (min) (cycle)
1 120.00 4000.00 10.00 16.00 82.14 81.7261
Fig. 4 TEM micrograph of drug loaded nanoemulsion
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Fig. 5 The mean stability of particle size as a function of time for the 
formulations 4 °C
Fig. 6 Effect of drug concentration on cell viability of 3T3 (a) and 
Hep G2 cell (b)
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the solution was kept under moderate magnetic stirring 
at 400 rpm for 24 h. Finally, the sample was centrifuged at 
4000 rpm for 30 min.
Preparation of nanoemulsions
The nanoemulsion containing Sorafenib was formulated 
with MCT and lecithin as the disperse phase and deion-
ized water, while Polysorbate 80 and glycerol was treated 
as the continuous phase. 0.5% (w/w) Sorafenib was first 
dissolved into 5% (w/w) MCT followed by 2% (w/w) 
lecithin with magnetic stirring, at 50 °C. This result was 
added into the aqueous phase containing 1% Polysorb-
ate 80 and 2.5% glycerol and subsequently blended using 
overhead stirring time (IKA®RW 20 Digital, Nara, Japan). 
The samples were subjected to further processing using 
high shear and high-pressure homogenizer. The samples 
were subjected to further processing using high shear 
and high-pressure homogenizer.
Particle size measurement
A Nano ZS90 (Malvern, UK) was utilized for the particle 
size measurement. The sensitivity range was 1–6000 nm. 
The particle size distribution was characterized in terms 
of their mean particle size (Z-average diameter) at room 
temperature. The samples were diluted with distilled 
water (1:100 ratio), then they were placed in the capillary 
cell for measuring of particle size.
Experimental design
A rotatable design with a central composite of four fac-
tors was applied to optimize the approach of high energy 
processing involving the overhead stirring time (X1), high 
shear rate (X2), high shear time (X3), and the cycle of 
high-pressure homogenizer (X4). It has been determined 
that each one of the effects of these four parameters in 
the response variable, namely average particle size (Y1) of 
nanoemulsion containing Sorafenib. Thirty experimental 
runs according to the central composite rotatable design 
(CCRD) was utilized to determine the optimized levels 
of significant factors, and the interactions of these vari-
ables in a process developed by the Design Expert_ver-
sion 6.0.6 software (Stat-Ease Inc., Minneapolis, USA). 
Four independent variables were carried out at five dif-
ferent levels for every individual variable. The central 
composite rotatable design les us study the impact of 
variables and interaction between variables in the results 
independently. Table 4 represents the coded independent 
variables. The optimal repetition model was verified by 
repeating the center point in duplicates.
Transmission electronic microscopy
Nanoemulsion formulation containing Sorafenib was 
characterized by high-resolution transmission electron 
microscope (TEM) with the operating system to cap-
ture the morphology of the colloidal system. The diluted 
nanoemulsion formulation was placed on a carbon-
coated copper grid supported with formvar films and 
allowed to stand for 2 min. Filled carbon-coated copper 
grid was negatively stained with 1% (w/v) uranyl acetate 
allowed to stand for 2  min. The carbon-coated copper 
grids examined with transmission electron microscopy 
(Hitachi H-7100, Japan).
Stability assessment
Stability of nanoemulsion containing Sorafenib was 
determined by observing the changes of particle size, 
drug precipitation, and color changing during storage. 
Studying The effect of the temperature on the long term 
stability of formulation were stored at 4 ± 2, 25 ± 2 and 
45 ± 2 °C for 90 days. The particle size of the nanoemul-
sions was also was monitored for 1, 30, 60 and 90 days 
to identify the variation the size of the particle over 
time.
MTT assay
Nanoemulsion with Sorafenib was placed in each well at 
various concentrations of 1.56, 3.125, 6.25, 12.5, 25, 50, 
and 100 μg/ml, respectively. The periods of utilized incu-
bation were 24 and 48 h. Yellow MTT [3-(4,5-Dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole] 
turns to purple formazan in the mitochondria living cells. 
The absorbance of the nanoemulsion [Optical Density 
(OD)] can be quantified by measuring a certain wave-
length (570  nm) three times for each sample by ELISA. 
The max absorption depends on the solvent [28]. The 
cytotoxicity was documented as the drug concentration 
which causes 50% of the tumor cell‘s growth inhibition 
(IC50 value) according to Eq. 2.
Table 4 Level of independent variables for using RSM
Symbol Independent variable Level of variables
−2 −1 0 +1 +2
X1 Overhead stirring time 80 120 160 200 240
X2 Shear rate 800 2000 3200 4400 5600
X3 Shear time 10 15 20 25 30
X4 Cycle of homogenizer 8 11 14 17 20
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After the cell viability is determined, the graphs were 
plotted with the cell viability’s percentage compared to 
their respective concentration.
Abbreviations
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